Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
出版年份 2022 全文链接
标题
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-02-11
DOI
10.1016/s1470-2045(22)00019-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
- (2021) Joseph Mikhael et al. Blood Cancer Journal
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
- (2021) Philippe Moreau et al. LANCET
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
- (2021) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- The Circular Life of Human CD38: From Basic Science to Clinics and Back
- (2020) Alberto L. Horenstein et al. MOLECULES
- Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
- (2020) Chen Zhu et al. Frontiers in Immunology
- Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
- (2019) Philippe Moreau et al. Blood Cancer Journal
- Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
- (2019) Thomas G. Martin et al. Cells
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
- (2018) Paul G Richardson et al. Future Oncology
- Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
- (2017) Antonella Chillemi et al. Frontiers in Immunology
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus
- (2016) P. Musto et al. ANNALS OF ONCOLOGY
- Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
- (2016) M. A. Dimopoulos et al. BLOOD
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
- (2015) Bryan Oronsky et al. NEOPLASIA
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation